Harel Insurance Investments & Financial Services Ltd. Takes $31,000 Position in Bristol Myers Squibb Company (NYSE:BMY)

Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the first quarter, Holdings Channel reports. The firm purchased 504 shares of the biopharmaceutical company’s stock, valued at approximately $31,000.

A number of other institutional investors and hedge funds also recently modified their holdings of BMY. Pinney & Scofield Inc. purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $26,000. Fairway Wealth LLC purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $28,000. Transce3nd LLC purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $28,000. Finally, Global Wealth Strategies & Associates increased its position in shares of Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 275 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of research analyst reports. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Cantor Fitzgerald reissued a “neutral” rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Jefferies Financial Group decreased their target price on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. Wall Street Zen downgraded Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $58.00.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the company’s stock in a transaction that occurred on Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president owned 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $47.02 on Friday. Bristol Myers Squibb Company has a one year low of $39.50 and a one year high of $63.33. The business has a fifty day moving average price of $47.73 and a 200-day moving average price of $53.60. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The firm has a market capitalization of $95.68 billion, a P/E ratio of 17.61, a PEG ratio of 1.39 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm’s quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the company earned ($4.40) earnings per share. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.27%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio is 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.